Stay updated on Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial page.

Latest updates to the Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated to version 2.16.5, and the previous version 2.16.4 has been removed. Additionally, a note regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference0.8%
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.6%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check41 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check69 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check83 days agoChange DetectedThe webpage has been updated to reflect a new phase II trial evaluating the anti-tumor activity of pembrolizumab and tamoxifen in patients with hormone receptor positive, HER2 negative metastatic breast cancer. Key details about the study's focus on immune checkpoint inhibitors and the involvement of specific investigators have been added.SummaryDifference55%
Stay in the know with updates to Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembro & Tamoxifen in ESR1+ Breast Cancer Clinical Trial page.